BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”, the "Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.

Piper Sandler 36th Annual Healthcare Conference

Fireside Chat Date: Tuesday, December 3rd, 2024

Fireside Chat Time: 1:30 PM ET

Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Location: New York City, NY

The live fireside chat can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

FLORetina ICOOR 2024

Florence, Italy

  • 48-week Results from the HELIOS Phase I Trial Evaluating Intravitreal OTX-TKI for Non-proliferative Diabetic Retinopathy

    Session: Highlighted New Drugs DME

    Presentation Date/Time: Thursday, December 5, 2024, 1:33 - 1:36PM CET

    Presenter: Dilsher S. Dhoot, MD

  • OTX-TKI - The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)

    Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates

    Presentation Date/Time Friday, December 6, 2024, 11:29 - 11:33AM CET

    Presenter: Diana V. Do, MD

  • HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR

    Session: Retina Futura 2: Diabetic Retinal Diseases and Retinal Detachment

    Presentation Date/Time: Friday, December 6, 2024, 2:12 - 2:16PM CET

    Presenter: Dilsher S. Dhoot, MD

  • TKIs in the Future of Retinal Disease Management

    Session: Afternoon Symposium

    Session Date/Time: Saturday, December 7, 2024, 3:30 - 4:30 PM CET

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular's product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular's pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations

[email protected]